Cellino
Vision
Democratize stem cell-based regenerative medicines for all patients.
Approach
Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format. This approach will enable the parallel processing of thousands of patient samples in a single facility, which is vital for scalable manufacturing. Cellino’s stem cell-derived therapies are poised to potentially cure some of the most burdensome diseases this decade, including Parkinson’s, diabetes, and heart disease. Current stem cell therapies are not scalable due to extensive manual handling, high variability, and expensive manufacturing overhead costs.
CEO:
Nabiha Saklayen, PhD
Founders:
Nabiha Saklayen, PhD (Co-founder)
Marinna Madrid, PhD (Co-founder)
Matthias Wagner (Co-founder)
First investment:
November 2021